Fineline Cube

Follow:
14855 Articles
Alfasigma Reclaims Sulodexide Rights in China – Business Transfer to Add €25 Million in Annual Revenue and Drive 30 % Expansion of Alfasigma China
CompanyDeals

Alfasigma Reclaims Sulodexide Rights in China – Business Transfer to Add €25 Million in Annual Revenue and Drive 30 % Expansion of Alfasigma China

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound
Company

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD
CompanyDrug

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications
CompanyDeals

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications

Lifetech Scientific Wins CE MDR Certification for IBS Absorbable Drug‑Eluting Coronary Stent – World's First Iron‑Based Bioresorbable Coronary Stent Approved
CompanyMedical Device

Lifetech Scientific Wins CE MDR Certification for IBS Absorbable Drug‑Eluting Coronary Stent – World’s First Iron‑Based Bioresorbable Coronary Stent Approved

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full
CompanyDeals

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI
CompanyDeals

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry's Largest Deal of Its Kind
CompanyDeals

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry’s Largest Deal of Its Kind

CSPC Reports Positive Top‑Line Phase III Data for Prusogliptin/Dapagliflozin/Metformin Triple Combination – Superior Glycemic Control in Type 2 Diabetes
CompanyDrug

CSPC Reports Positive Top‑Line Phase III Data for Prusogliptin/Dapagliflozin/Metformin Triple Combination – Superior Glycemic Control in Type 2 Diabetes

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates
CompanyDeals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

CSPC Pharmaceutical Initiates Phase I Clinical Trial of SYS6057 – Self‑Developed Recombinant RSV Vaccine with Dual‑Subtype Preclinical Protection
CompanyDrug

CSPC Pharmaceutical Initiates Phase I Clinical Trial of SYS6057 – Self‑Developed Recombinant RSV Vaccine with Dual‑Subtype Preclinical Protection

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion